Yahoo
HKSE - Delayed Quote HKD

Shanghai Bio-heart Biological Technology Co., Ltd. (2185.HK)

0.980 -0.010 (-1.01%)
As of November 6 at 3:56:23 PM GMT+8. Market Open.
Chart Range Bar
Loading chart for 2185.HK
  • Previous Close 0.990
  • Open 1.000
  • Bid 0.975 x --
  • Ask 1.000 x --
  • Day's Range 0.980 - 1.040
  • 52 Week Range 0.930 - 8.100
  • Volume 47,400
  • Avg. Volume 94,628
  • Market Cap (intraday) 238.549M
  • Beta (5Y Monthly) 0.18
  • PE Ratio (TTM) --
  • EPS (TTM) -0.320
  • Earnings Date --
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est --
  • Moby Rating Neutral

Shanghai Bio-heart Biological Technology Co., Ltd., together with its subsidiaries, engages in the research, development, and commercialization of invasive treatment products in China. The company develops Bioheart, a bioresorbable scaffolds system, which is in registration stage for percutaneous coronary intervention procedures for the treatment of coronary artery disease; Iberis, a renal denervation system, which is in clinical stage for the treatment of uncontrolled hypertension and resistant hypertension; and DCB, a sirolimus drug coated balloon catheter, which is in clinical stage for the treatment of instent restenosis. It is also involved in local administration and manufacturing services. The company was founded in 2014 and is headquartered in Shanghai, China.

www.bio-heart.com

63

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Medical Devices

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 11/9/2026, which may include dividends or other distributions. Benchmark is HANG SENG INDEX (^HSI) .

YTD Return

2185.HK
82.28%
HANG SENG INDEX (^HSI)
4.27%

1-Year Return

2185.HK
87.90%
HANG SENG INDEX (^HSI)
6.50%

3-Year Return

2185.HK
73.87%
HANG SENG INDEX (^HSI)
40.11%

5-Year Return

2185.HK
94.81%
HANG SENG INDEX (^HSI)
1.12%

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -196.37%

  • Return on Assets (ttm)

    -6.59%

  • Return on Equity (ttm)

    -12.16%

  • Revenue (ttm)

    38.45M

  • Net Income Avi to Common (ttm)

    -75.5M

  • Diluted EPS (ttm)

    -0.320

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    237.88M

  • Total Debt/Equity (mrq)

    1.99%

  • Levered Free Cash Flow (ttm)

    -86.28M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: